Company: PIII
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001140361-25-014596
Chunk: 48

Company: P3 Health Partners Inc.
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 48
---
 on change in ASC 718 Fair Value from Prior 
 FY End to Vesting Date                                                                                                                              |     |      | — |     |              |        — |   |     |      |        — |   |     |              |  (34,500 | ) |     |      |          — |   |     |              |        — |   |
| TOTAL ADJUSTMENTS                                                                                                                                   |     | $    | — |     | $            | (360,935 | ) |     | $    |        — |   |     | $            | (345,750 | ) |     | $    | (6,397,533 | ) |     | $            |  (90,194 | ) |

| (3) | The amounts reflect the cumulative total shareholder return (“TSR”) of our Common Stock at the end of each fiscal year. The TSR value listed in each year reflects what the cumulative value of $100 would be                           
 if invested on December 31, 2021. TSR is calculated on a cumulative basis by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment (if any), and the difference between the 
 Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. Historical stock price performance is not necessarily indicative of future stock  
 performance.                                                                                                                                                                                                                            |

| (4) | The dollar amounts reported represent the net income (loss) reflected in the Company’s audited financial statements for the applicable year. |

31 Relationship Between Compensation Actually Paid and Financial Performance Measures Practices for the Timing of Awards as They Relate to the Disclosure of Material Non-Public Information We do not grant equity awards in anticipation of the release of material nonpublic informationand we do not time the release of material nonpublic information based on equity award grant dates or for the purpose of affecting the value of executive compensation.In addition, we do not take material nonpublic information into account when determining the timing and terms of such awards. Although we do not have a formal policy with respect to the timing of our equity award grants, the Compensation and Nominating Committee anticipates that it will grant most awards on a predetermined annual schedule. In fiscal 2024, we granted an award of stock options to one of our named executive officers in the period beginning four business days before the filing or furnishing of a periodic report or current report disclosing material nonpublic information and ending one business day after the filing or furn